Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Immunocore Holdings (IMCR) EBITDA: 2021-2025

Historic EBITDA for Immunocore Holdings (IMCR) over the last 3 years, with Sep 2025 value amounting to -$3.6 million.

  • Immunocore Holdings' EBITDA fell 129.78% to -$3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$28.1 million, marking a year-over-year decrease of 23.06%. This contributed to the annual value of -$48.6 million for FY2024, which is 31.77% down from last year.
  • Immunocore Holdings' EBITDA amounted to -$3.6 million in Q3 2025, which was up 6.67% from -$3.8 million recorded in Q2 2025.
  • Immunocore Holdings' 5-year EBITDA high stood at $12.0 million for Q3 2024, and its period low was -$26.4 million during Q4 2024.
  • Moreover, its 3-year median value for EBITDA was -$10.2 million (2023), whereas its average is -$7.9 million.
  • The largest annual percentage gain for Immunocore Holdings' EBITDA in the last 5 years was 185.32% (2024), contrasted with its biggest fall of 4,508.57% (2024).
  • Quarterly analysis of 4 years shows Immunocore Holdings' EBITDA stood at $18,000 in 2021, then reached -$572,000 in 2023, then plummeted by 4,508.57% to -$26.4 million in 2024, then tumbled by 129.78% to -$3.6 million in 2025.
  • Its last three reported values are -$3.6 million in Q3 2025, -$3.8 million for Q2 2025, and $5.7 million during Q1 2025.